NO20053455L - Anvendelse av en kombinasjon inneholdende en ikke-nukleosid revers transkriptase inhibitor (NNRTI) med en inhibitor av cytokrom P450 sa som protease inhibitorer - Google Patents
Anvendelse av en kombinasjon inneholdende en ikke-nukleosid revers transkriptase inhibitor (NNRTI) med en inhibitor av cytokrom P450 sa som protease inhibitorerInfo
- Publication number
- NO20053455L NO20053455L NO20053455A NO20053455A NO20053455L NO 20053455 L NO20053455 L NO 20053455L NO 20053455 A NO20053455 A NO 20053455A NO 20053455 A NO20053455 A NO 20053455A NO 20053455 L NO20053455 L NO 20053455L
- Authority
- NO
- Norway
- Prior art keywords
- inhibitor
- nnrti
- cytochrome
- reverse transcriptase
- protease inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43369002P | 2002-12-16 | 2002-12-16 | |
PCT/EP2003/014224 WO2004054586A1 (en) | 2002-12-16 | 2003-12-15 | Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20053455L true NO20053455L (no) | 2005-08-10 |
Family
ID=32595224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20053455A NO20053455L (no) | 2002-12-16 | 2005-07-15 | Anvendelse av en kombinasjon inneholdende en ikke-nukleosid revers transkriptase inhibitor (NNRTI) med en inhibitor av cytokrom P450 sa som protease inhibitorer |
Country Status (20)
Country | Link |
---|---|
US (2) | US20040152625A1 (zh) |
EP (1) | EP1575595A1 (zh) |
JP (1) | JP2006511538A (zh) |
KR (1) | KR20050085681A (zh) |
CN (1) | CN1726041A (zh) |
AU (1) | AU2003296647A1 (zh) |
BR (1) | BR0317095A (zh) |
CA (1) | CA2510143A1 (zh) |
EA (1) | EA200500894A1 (zh) |
EC (1) | ECSP055854A (zh) |
HR (1) | HRP20050557A2 (zh) |
IL (1) | IL169099A0 (zh) |
MX (1) | MXPA05005773A (zh) |
NO (1) | NO20053455L (zh) |
NZ (1) | NZ541187A (zh) |
PL (1) | PL376900A1 (zh) |
RS (1) | RS20050461A (zh) |
UA (1) | UA81003C2 (zh) |
WO (1) | WO2004054586A1 (zh) |
ZA (1) | ZA200502947B (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1944042A1 (en) | 2003-10-27 | 2008-07-16 | Vertex Pharmceuticals Incorporated | Combinations for HCV treatment |
US7388008B2 (en) | 2004-08-02 | 2008-06-17 | Ambrilia Biopharma Inc. | Lysine based compounds |
EP1877091B1 (en) * | 2005-04-27 | 2015-03-25 | TaiMed Biologics, Inc. | Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors |
CN101405293B (zh) | 2005-11-30 | 2013-03-13 | 中裕新药股份有限公司 | 天冬氨酰基蛋白酶抑制剂基于赖氨酸的前体药物及其制备方法 |
CN1907138B (zh) * | 2006-08-11 | 2011-01-12 | 华南师范大学 | 一种沙田柚子汁提取物及其提取方法和应用 |
JP5401652B2 (ja) | 2006-09-21 | 2014-01-29 | タイメッド バイオロジクス インコーポレイテッド | プロテアーゼ阻害剤 |
MY160130A (en) | 2009-02-27 | 2017-02-28 | Enanta Pharm Inc | Hepatitis c virus inhibitors |
TWI468160B (zh) * | 2009-04-25 | 2015-01-11 | Hoffmann La Roche | 增進藥物動力學之方法 |
WO2010132163A1 (en) | 2009-05-13 | 2010-11-18 | Enanta Pharmaceuticals, Inc. | Macrocyclic compounds as hepatitis c virus inhibitors |
EP2512480A4 (en) | 2009-12-14 | 2013-05-15 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
WO2014013014A1 (en) | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
US20220177978A1 (en) | 2019-04-02 | 2022-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
US20220202820A1 (en) | 2019-04-16 | 2022-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels |
WO2023222565A1 (en) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5539122A (en) * | 1989-05-23 | 1996-07-23 | Abbott Laboratories | Retroviral protease inhibiting compounds |
IL111991A (en) * | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
US6037157A (en) * | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
US6410546B1 (en) * | 1997-04-07 | 2002-06-25 | Triangle Pharmaceuticals, Inc. | Use of MKC-442 in combination with other antiviral agents |
CN1154491C (zh) * | 1998-11-04 | 2004-06-23 | 法玛西雅厄普约翰美国公司 | 用于改善替普拉那维的药物动力学的方法 |
US6391919B1 (en) * | 2000-01-12 | 2002-05-21 | Bristol-Myers Squibb Pharma Company | Bis-amino acid sulfonamides containing substituted benzyl amines HIV protease inhibitors |
TWI270547B (en) * | 2000-06-16 | 2007-01-11 | Boehringer Ingelheim Ca Ltd | Non-nucleoside reverse transcriptase inhibitors |
WO2004085437A1 (en) * | 2002-09-19 | 2004-10-07 | Boehringer Ingelheim (Canada) Ltd. | Non-nucleoside reverse transcriptase inhibitors |
-
2003
- 2003-12-15 NZ NZ541187A patent/NZ541187A/en unknown
- 2003-12-15 KR KR1020057011003A patent/KR20050085681A/ko not_active Application Discontinuation
- 2003-12-15 EA EA200500894A patent/EA200500894A1/ru unknown
- 2003-12-15 US US10/736,301 patent/US20040152625A1/en not_active Abandoned
- 2003-12-15 BR BR0317095-0A patent/BR0317095A/pt not_active IP Right Cessation
- 2003-12-15 UA UAA200507057A patent/UA81003C2/uk unknown
- 2003-12-15 RS YUP-2005/0461A patent/RS20050461A/sr unknown
- 2003-12-15 MX MXPA05005773A patent/MXPA05005773A/es not_active Application Discontinuation
- 2003-12-15 WO PCT/EP2003/014224 patent/WO2004054586A1/en not_active Application Discontinuation
- 2003-12-15 EP EP03813119A patent/EP1575595A1/en not_active Withdrawn
- 2003-12-15 CA CA002510143A patent/CA2510143A1/en not_active Abandoned
- 2003-12-15 PL PL376900A patent/PL376900A1/pl not_active Application Discontinuation
- 2003-12-15 CN CNA2003801063012A patent/CN1726041A/zh active Pending
- 2003-12-15 JP JP2004560402A patent/JP2006511538A/ja active Pending
- 2003-12-15 AU AU2003296647A patent/AU2003296647A1/en not_active Abandoned
-
2005
- 2005-04-12 ZA ZA200502947A patent/ZA200502947B/en unknown
- 2005-06-09 IL IL169099A patent/IL169099A0/en unknown
- 2005-06-15 HR HR20050557A patent/HRP20050557A2/xx not_active Application Discontinuation
- 2005-06-15 EC EC2005005854A patent/ECSP055854A/es unknown
- 2005-07-15 NO NO20053455A patent/NO20053455L/no not_active Application Discontinuation
-
2007
- 2007-10-25 US US11/923,699 patent/US20080096832A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20080096832A1 (en) | 2008-04-24 |
MXPA05005773A (es) | 2005-08-16 |
CA2510143A1 (en) | 2004-07-01 |
KR20050085681A (ko) | 2005-08-29 |
CN1726041A (zh) | 2006-01-25 |
UA81003C2 (en) | 2007-11-26 |
ECSP055854A (es) | 2006-01-16 |
HRP20050557A2 (en) | 2006-05-31 |
NZ541187A (en) | 2007-12-21 |
EP1575595A1 (en) | 2005-09-21 |
PL376900A1 (pl) | 2006-01-09 |
EA200500894A1 (ru) | 2006-02-24 |
AU2003296647A1 (en) | 2004-07-09 |
BR0317095A (pt) | 2005-10-25 |
WO2004054586A1 (en) | 2004-07-01 |
IL169099A0 (en) | 2007-07-04 |
ZA200502947B (en) | 2008-01-30 |
US20040152625A1 (en) | 2004-08-05 |
JP2006511538A (ja) | 2006-04-06 |
RS20050461A (en) | 2007-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20053455L (no) | Anvendelse av en kombinasjon inneholdende en ikke-nukleosid revers transkriptase inhibitor (NNRTI) med en inhibitor av cytokrom P450 sa som protease inhibitorer | |
DK0871465T3 (da) | Anvendelse af ritonavir (ABT-538) til at forbedre farmakokinetikken af lægemidler, som metaboliseres af cytochrom P450, i en metode til behandling af AIDS | |
EA200401043A1 (ru) | Лечение доброкачественной гиперплазии простаты селективным модулятором рецептора андрогенов ( sarm ) | |
NO20052690D0 (no) | Fenylalaninderivater som dipeptidylpeptidaseinhibitorer for behandlingen eller profylaksen av sukkersyke. | |
CY1110690T1 (el) | Ενωσεις 4-οξοκινολινης και χρησιμοποιηση αυτων ως αναστολεις της ενσωματασης του hiv | |
ECSP034922A (es) | Pirrolopirimidinas | |
NO20060416L (no) | Ny anvendelse I | |
NO20040021L (no) | Beta-amino-tetrahydroimidaz(1,2-a)pyraziner og tetrahydrotriazolo(4,3-a)pyraziner, farmasøytiske preparater som omfatter forbindelsene, og anvendelse av forbindelsene ved fremstilling av medikamenter for anvendelse ved behandling av sukkersyke type II. | |
TW200510425A (en) | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | |
NO20025601L (no) | Arylmetylaminderivater for anvendelse som tryptaseinhibitorer | |
NO20092636L (no) | Ikke-nukleosid-reverstranskriptaseinhibitorer | |
IL158559A0 (en) | Acne treatment | |
NO20044889L (no) | Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease | |
NO20073628L (no) | Pyridoner som er nyttige som inhibitorer av kinaser | |
HUP0202570A1 (hu) | Izoflavonokat és analogonjait tartalmazó készítmények és terápiás alkalmazásuk | |
NO20055000L (no) | Fremgangsmate for a hindre varme oppblusinger ved anvendelse av prodrug av gaba-analoger | |
NO20090322L (no) | 6-(heterosykel-substituert benzyl)-4-oksoquinolin forbindelse samt anvendelse av det samme som IIIV integrave inhibitor | |
NO20090405L (no) | Ikke-nukleoside revers transcriptase inhibitorer | |
NO20072934L (no) | Anvendelse av Ranolazon i kombinasjon med minst ett remodelleringsmiddel for a reversere remodellering av venstre ventikkel ved behandlingen av hjertesvikt | |
DK1949893T3 (da) | Quinazolinderivater, der kan anvendes til behandling af perifer arteriel sygdom og som phosphodiesteraseinhibitorer | |
UY26422A1 (es) | Método para administrar un inhibidor de fosfodiesterasa 4 | |
NO20052313L (no) | Vandig farmasoytisk formulering omfattende trombininhibitorer melagatran og anvendelse av formuleringen for fremstilling av et medikament for anvendelse i nasal administrering i behandling av | |
HUP0401091A2 (hu) | Atazanavir alkalmazása HIV-terápiában | |
EA199700150A1 (ru) | КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ ПО ПОВОДУ ВИЧ ИНФЕКЦИИ С ИСПОЛЬЗОВАНИЕМ ИНГИБИТОРА ПРОТЕАЗЫ ВИЧ ИНДИНАВИРА И ИНГИБИТОРА ОБРАТНОЙ ТРАНСКРИПТАЗЫ 3TC, НЕОБЯЗАТЕЛЬНО СОВМЕСТНО С AZT, ddI ИЛИ ddC | |
UY26648A1 (es) | Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |